Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

被引：1
作者：
El-Ghazzi, Nathan [1 ]
Lavaud, Pernelle [2 ]
机构：
[1] Univ Clermont Auvergne, Med Oncol Serv, Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 03期
关键词：
Non-small-cell lung carcinoma; Immunotherapy; Checkpoint immune inhibitors; Chemotherapy; PLATINUM-DOUBLET CHEMOTHERAPY; PLUS IPILIMUMAB;
D O I：
10.1016/j.bulcan.2021.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 233
页数：4
相关论文
共 7 条
  • [1] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
  • [2] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2020 - 2031
  • [3] Larkin J, 2019, N ENGL J MED, V381
  • [4] Motzer RJ, 2018, N ENGL J MED, V378
  • [5] Ramalingam SS, 2020, JCO S, V38
  • [6] Reck M, 2020, JCO S, V38
  • [7] Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    Reck, Martin
    Mok, Tony S. K.
    Nishio, Makoto
    Jotte, Robert M.
    Cappuzzo, Federico
    Orlandi, Francisco
    Stroyakovskiy, Daniil
    Nogami, Naoyuki
    Rodriguez-Abreu, Delvys
    Moro-Sibilot, Denis
    Thomas, Christian A.
    Barlesi, Fabrice
    Finley, Gene
    Lee, Anthony
    Coleman, Shelley
    Deng, Yu
    Kowanetz, Marcin
    Shankar, Geetha
    Lin, Wei
    Socinski, Mark A.
    [J]. LANCET RESPIRATORY MEDICINE, 2019, 7 (05) : 387 - 401
1